课题基金 / 基金详情

Pathophysiological Analysis of CD36 Deficiency As a Novel Cause of Idiopathic Cardiomyopathy; Role of Long-chain Fatty Acid Transporter, CD36, in Myocardial Energy Metabolism

Pathophysiological Analysis of CD36 Deficiency As a Novel Cause of Idiopathic Cardiomyopathy; Role of Long-chain Fatty Acid Transporter, CD36, in Myocardial Energy Metabolism
CD36 缺乏作为特发性心肌病新病因的病理生理学分析;
批准号:
10671070
负责人:
YAMASHITA Shizuya
金额:
$2.37万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1998
资助国家:
日本
项目状态:
已结题
起止时间:
1998 至 1999

项目摘要

项目成果

YAMASHITA Shizuya的其他基金

相似基金

相关文献

中文摘要
翻译
CD36是88 kDa membrane glycoprotein and is expressed on platelets, monocytes,monocyed -derived macrophages and adipose tissues. CD36 was reported to be a receptor for collagenthrombospondin as as a transporter of long-chain fatty acids.我们有标识的patientswith CD36 deficiency and reported 3 novel mutations in the CD36 gene. We also found that CD36 is areceptor for oxidized LDL,使用monocyte-derived macrophages from CD36-deficient subjects and that CD36是expressed on foamedmacrophages in the human atherosclerotic aorta and coronary arterise.我们经常发现的是CD36expressed on the cardiac myocytes. CD36-deficient subjects lack CD36 on the cardiomyocytes and some他们develop idiopathic cardiomyopathy. So far, we identified 26cd36 -deficient subjects,all of whom showed a complete deficiency of myocardial uptake of D1123 D1I-BMIPPlong-chain fatty acid analogue. Six subjects were accompanied by hypertrophic or dilatedcardiomyopathy. FDG-PET anlysis demonstrated that glucose uptake by the heart muscle was ratheraccelerated in the CD36-deficient subjects compared with conmtrol subjects. Thus,the impaired mayocardial uptake of long-chain fatty acids may lead to an energy switching fromlong-chain fatty acids to glucose in CD36 deficiency. to further examine the可能的贡献CD36 deficiency to the pathogenesis of cardiomyopathy,we are trying to establish CD36 knockout mice by genetic engineering technique we are planning toevaluate the presence or absence of impaired cardiac functioncardiac hypertrophy or dilated cardiomyopathy in this animal model to establish the significance ofCD36 deficiency in the pathogenesis of cardiomyopathy。
英文摘要
CD36 is an 88 kDa membrane glycoprotein and is expressed on platelets, monocytes, monocyte-derived macrophages and adipose tissues. CD36 was reported to be a receptor for collagen and thrombospondin as well as a transporter of long-chain fatty acids. We have identified patients with CD36 deficiency and reported 3 novel mutations in the CD36 gene. We also found that CD36 is a receptor for oxidized LDL, using monocyte-derived macrophages from CD36-deficient subjects and that CD36 is expressed on foamed macrophages in the human atherosclerotic aorta and coronary arterise. We also found that CD36 is expressed on the cardiac myocytes. CD36-deficient subjects lack CD36 on the cardiomyocytes and some of them develop idiopathic cardiomyopathy. So far, we identified 26 CD36-deficient subjects, all of whom showed a complete deficiency of myocardial uptake of ィイD1123ィエD1I-BMIPP, a long-chain fatty acid analogue. Six subjects were accompanied by hypertrophic or dilated cardiomyopathy. FDG-PET anlysis demonstrated that glucose uptake by the heart muscle was rather accelerated in the CD36-deficient subjects compared with conmtrol subjects. Thus, the impaired mayocardial uptake of long-chain fatty acids may lead to an energy switching from long-chain fatty acids to glucose in CD36 deficiency. To further examine the possible contribution of CD36 deficiency to the pathogenesis of cardiomyopathy, we are trying to establish CD36 knockout mice by genetic engineering technique. We are planning to evaluate the presence or absence of impaired cardiac function, cardiac hypertrophy or dilated cardiomyopathy in this animal model to establish the significance of CD36 deficiency in the pathogenesis of cardiomyopathy.
期刊论文(25)
专著(0)
科研奖励(0)
会议论文
A.Nakata,M.Nishida et al.: "CD36, a novel receptor for oxidized low density lipoproteins, is highly expressed on lipid-laden macrophages in human atherosclerotic aorta"Arterioscler Thromb Vasc Biol. 19. 1333-1339 (1999)
A.Nakata、M.Nishida 等人:“CD36 是氧化低密度脂蛋白的一种新型受体,在人动脉粥样硬化主动脉中的脂质巨噬细胞上高度表达”Arterioscler Thromb Vasc Biol。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
T. Yoshizumi, S. Yamashita, et al.: "Pharmacokinetics and metabolism of iodine-123-BMIPP fatty acid analogue in normal and CD36-deficient subjects"J Nucl Med. (in press).
T. Yoshizumi、S. Yamashita 等人:“碘-123-BMIPP 脂肪酸类似物在正常和 CD36 缺陷受试者中的药代动力学和代谢”J Nucl Med。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
T. Nakagawa, S. Yamashita et al.: "Oxidized LDL increases and interferon-γ decreases expression of CD36 in human monocyte-derived macrophages."Arterioscler Thromb Vasc Biol. 18. 1350-1357 (1998)
T. Nakakawa、S. Yamashita 等人:“氧化 LDL 增加,干扰素 γ 降低人单核细胞来源的巨噬细胞中 CD36 的表达。”18. 1350-1357 (1998)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
T.Nakata,Y.Nakagawa,et al: "CD36,a novel receptor for oxidized low density lipoproteins,is highly expressed on lipid-laden macrophages in human atherosclemtic aorta" Arterioscler Thromb Vasc Biol. in press. (1999)
T.Nakata、Y.Nakakawa 等人:“CD36 是氧化低密度脂蛋白的一种新型受体,在人动脉粥样硬化主动脉中的脂质巨噬细胞上高度表达”Arterioscler Thromb Vasc Biol。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
17
    Progranulin, a Novel HDL-Binding Protein, Suppresses Systemic Inflammation, Glucose Abnormality and Atherosclerosis
    • 批准号:
      24390233
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.48万
    • 财政年份:
      2012
    • 负责人:
      YAMASHITA Shizuya
    • 依托单位:
    Adiponectin prevents atherosclerosis by accelerating reverse cholesterol transport and HDL synthesis
    • 批准号:
      20390256
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.9万
    • 财政年份:
      2008
    • 负责人:
      YAMASHITA Shizuya
    • 依托单位:
    Development of Oxidized LDL Receptor (CD36) Knockout Mice and Its Application to Elucidation of Molecular Mechanism for Atherogenesis
    • 批准号:
      12835005
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.3万
    • 财政年份:
      2000
    • 负责人:
      YAMASHITA Shizuya
    • 依托单位:
    Establishment of A New Strategy for the Treatment of Atherosclerosis by Inhibition of an Oxidized LDL Receptor, CD36
    海外基金